Merus (NASDAQ:MRUS) COO Peter B. Silverman Sells 10,000 Shares of Stock

Merus (NASDAQ:MRUS) COO Peter B. Silverman sold 10,000 shares of the stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $60.00, for a total transaction of $600,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Merus Price Performance

NASDAQ MRUS opened at $59.17 on Friday. The company’s 50-day simple moving average is $50.49 and its two-hundred day simple moving average is $42.77. Merus has a one year low of $19.81 and a one year high of $61.61.

Merus (NASDAQ:MRUS) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.24. The business had revenue of $7.89 million for the quarter, compared to the consensus estimate of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. Analysts predict that Merus will post -3.1 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC increased its position in Merus by 37.7% during the 4th quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 343 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Merus by 64.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 828 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Merus by 2.9% in the 1st quarter. California State Teachers Retirement System now owns 33,745 shares of the biotechnology company’s stock valued at $1,520,000 after buying an additional 936 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Merus by 1.9% in the 1st quarter. Swiss National Bank now owns 74,054 shares of the biotechnology company’s stock valued at $3,335,000 after buying an additional 1,400 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Merus by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 5,753 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,459 shares in the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MRUS shares. Truist Financial increased their target price on shares of Merus from $69.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, June 4th. Guggenheim increased their target price on shares of Merus from $57.00 to $93.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. StockNews.com downgraded shares of Merus from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Bank of America reaffirmed a “buy” rating and issued a $76.00 price target on shares of Merus in a research note on Tuesday. Finally, Canaccord Genuity Group raised their price target on shares of Merus from $54.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $80.90.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.